CLIA ID#: 22D0950490 Lab Director: Mark D. Kellogg, PhD, DABCC www.claritasgenomics.com



GENERAL GENETIC TESTING REQUISITION FORM

PATIENT INFORMATION						
Last Name	First Name			MI	Gender □ Male □ Female	☐ Unknown
DOB (MM/DD/YY)	MRN	Phone	one number		Email	
Address		City			State Zip Code	
ORDERING PHYSICIAN	Mark If Preferred Contact					
Name				Institution		
NPI#	Specialty			Address		
Phone	Fax					
Email				City	State Zip Code	
GENETIC COUNSELOR	Mark If Preferred Contact					
Name				Email/	=ax	
ADDITIONAL RESULTS REC	CIPIENTS					
Name		Phone_		Email/	ax	
Name		Phone_	eEmail/F		- ax	
TEST SUBMISSION CHECK	LIST		SAMPLE INFO	RMATION		
☐ Patient and Sample Information	☐ ICD-10 Codes☐ Sample(s) with Two (2))	Patient Not all sample types are acceptable for all tests. See the Specime Requirements page on our website for more detailed information Specimen Type ☐ Whole Blood ☐ DNA ☐ Bone Marrow ☐ Saliva ☐ Blood Spot Card			
☐ Test Requested	Identifiers	.)				
☐ Billing Information	☐ Medical Records - Atta	ıch				
☐ Clinical Information Form	☐ Client Registration For	rm	Collection: Date Time:AM/PM (circle one) □ Check this box if the patient has ever had a bone marrow transplant.			e)
\square Signed Informed Consent	(new clients only)					
STATEMENT OF MEDICAL I	NECESSITY	\Box	Biological parental sa	amples may aid in the	interpretation of the patient's results. If p	
For Providers from NEW YORK a signature below is required.	<u>STATE,</u>		are marked 10 Be S	ent Later," testing will	proceed on the proband's sample.	
By sending this sample, I acknow	vledge that:		Mother		Father	
 I am a healthcare provider aut in the location that I practice; 	horized to order genetic test	ing	☐ Included☐ Not Available		ı □ Included □ Not Available	
This test is medically necessar	, ,	ion			1	
of a disease, illness, impairme disorder and that these results			- To be sent Le	MM/DD/Y	☐ To Be Sent Later, ETA	MM/DD/YY
management and treatment d		,	Name			
 I am responsible for returning the results of genetic testing to my patient and/or legal guardian and for ensuring that my patient receives appropriate genetic counseling to understand the implications of his/her test; The patient/legal guardian has been provided information regarding the risks/benefits and limitations of the test(s) ordered and the patient/legal guardian has given consent for the ordered test(s) to be performed; I have obtained all signatures as necessary under the laws of 		ny	DOB (MM/DD/YY)		DOB (MM/DD/YY)	
		and	Specimen Type	☐ Blood ☐ DN	A Specimen Type ☐ Bloo	d 🗆 DNA
				☐ Saliva	☐ Saliv	
		for	Collection: Date		Collection: Date	
):	Time:_	
my state;	,		Clinical Present	ation	☐ Clinical Presentation☐ Unaffected	
 Upon request I am able to produce the patient/guardian. 	duce the consent form signe	d by	☐ Unaffected☐ Not Evaluated	d	□ Not Evaluated	
2 Jeanna Garagan			☐ Affected - Atta		☐ Affected - Attach Deta	ails
PROVIDER SIGNATURE	DATE (MM/DD/YY)	—	55.55	= 3.03	1	
	27 TE (MM) 00/11)					

CLARITAS GENOMICS INC. | 99 Erie Street Cambridge, MA 02139 | e: clientservices@claritasgenomics.com | p: 617.553.5880 p: 855.373.9003 f: 617.553.5842
© 2016 ALL RIGHTS RESERVED | CG-GGT-0816



Test Requested

Sanger Sequencing-Complete Gene	Test Code	□ PTEN	S0508
□ ALX3	S0801	□ PTPN11	S0204
□ ARX	S0962	□ RAF1	S0690
□ CDKL5	S0231	□ ROBO3	S0202
□ CHD7	S0368	□ RPL11	S0055
□ CHN1	S0821	□ RPL5	S0510
□ COL1A1	S0311	□ RPS19	S0804
□ COL1A2	S0640	□ RPS24	S0095
☐ CYP24A1	S0011	□ SALL4	S0101
□ DCX	S0846	□SBDS	S0182
☐ DHCR7	S0752	□ SCN1B	S0093
□ ELANE	S0524	□ SLC26A3	S0372
□ ERCC6	S0161	☐ SLC26A4	S0587
□ ERCC8	S0948	□ SLC9A6	S0968
☐ F13A1	S0218	□ SMPD1	S0401
	S0961	□ S0S1	S0584
☐ FANCA	S0715	□ SPRED1	S0749
☐ FANCC	S0348	☐ SYNGAP1	S0171
☐ FANCG	S0075	☐ TBX22	S0418
☐ FGFR2	S0845	☐ TCF4	S0902
FLNA	S0013	☐ TMPRSS6	S0574
□ FOXG1	S0823	□ TUBB3	S0983
□ GAA	S0249	☐ TWIST1	S0313
☐ GABRG2	S0531	□TYR	S0896
☐ GALT	S0903	□ UBE3A	S0104
☐ GATA1	S0740	□ XPA	S0004
□ GBA	S0613	□XPC	S0270
☐ GJB2 [Connexin 26]	S0908		
□ GLA	S0128	Deletion/Duplication Analysis	Test Code
GPR56	S0918	☐ 1p36 Deletion/Duplication	C0822
☐ HAX1	S0864	☐ 1q21 Deletion/Duplication	C0121
□ HOXA1	S0390	☐ 15q13.2q13.3 Deletion/Duplication	C0387
□IDUA	S0495	☐ 16p11.2 Deletion/Duplication	C0116
□ IRF6	S0074	☐ 17q12 Deletion/Duplication	C0109
☐ JAG1	S0581	☐ 17q21 Deletion/Duplication	C0552
☐ KRAS	S0713	☐ Angelman/ Prader-Willi Syndrome Methylation	C0703
☐ MECP2	S0440	and Deletion/Duplication	
☐ MSX1	S0900	[15q11q13] □ Cri du Chat Syndrome Deletion [5p-]	C0247
□ NLGN3	S0483	☐ DCX Deletion/Duplication	C0593
□ NLGN4	S0050	□ DMD Deletion/Duplication	C0507
□ NPHP1	S0339	☐ ERCC6 Deletion/Duplication	C0404
□ NSD1	S0544	□ ERCC8 Deletion/Duplication	C0689
□ OCA2	S0212	☐ FLNA Deletion/Duplication	C0569
□ PHOX2A	S0773	☐ GALT Deletion/Duplication	C0046





Test Requested continued

☐ GJB6 Deletion [Connexin 30]	T0852
□ JAG1 Deletion/Duplication	C0711
☐ Langer-Giedion Syndrome Deletion [TRPS1, EXT1]	C0049
☐ MECP2 Deletion/Duplication	C0105
☐ Miller-Dieker Syndrome Deletion [17p13.3]	C0975
☐ NF1 Deletion/Duplication	C0582
☐ NF2 Deletion/Duplication	C0699
☐ NSD1 Deletion/Duplication	C0736
☐ PMP22 Deletion/Duplication	C0998
☐ PTEN Deletion/Duplication	C0466
☐ Rubinstein-Taybi Syndrome Deletion [16p13.3]	C0291
☐ Smith-Magenis Syndrome Deletion [17p11.2]	C0304
☐ SMN1 Exon 7 Deletion/Duplication	T0996
☐ SPRED1 Deletion/Duplication	C0905
☐ TCF4 Deletion/Duplication	C0265
☐ TWIST1 Deletion/Duplication	C0537
☐ Velocardiofacial/ DiGeorge Syndrome Deletion/Duplication [10p13-p14, 22q11.2]	C0207
☐ WAGR Syndrome Deletion [11p13]	C0108
☐ Williams Syndrome Deletion [7q11.2]	C0253
☐ Wolf-Hirschhorn Syndrome Deletion [4p-]	C0272

☐ Mitochondrial tRNA-Leu (MT-TL1) Variants	T0167
☐ Mitochondrial tRNA-Lys (MT-TK) Variants	T0014
☐ Mitochondrial tRNA-Ser (MT-TS1) Variants	T0419
☐ MTHFR Thermolabile Variant Analysis	T0027
☐ Muenke Syndrome Variant Analysis	T0285
☐ Pfeiffer syndrome FGFR1 Variant Analysis	T0810
☐ Prothrombin Variant Analysis	T0577

Other	Test Code
☐ ClariView Array (Microarray)	C0744
☐ FMR1 CCG Repeat Analysis (Fragile X Testing)	T0220
□ OCA2 2.7 kb Deletion	T0363
☐ TPMT Haplotype Analysis	T0958
☐ UGT1A TA Repeat Analysis	T0958
☐ Y Chromosome Sequence Detection [SRY, TTTY11, DDX3Y]	T0043

Use our Exome-Based Testing Requisition form to order the Claritas Clinical Exome, our whole exome sequencing test, as well as our Region of Interest tests that focus on specific pediatric rare inherited diseases.

,	
CLIA Confirmation of Research Findings	Call to discuss
☐ Using Existing Primers	
☐ Using Custom-Designed Primers	
Gene name:	
Variant(s) in HGVS nomenclature:	
NM# used for variant analysis:	
Protocol used (examples: Sanger, forward primer sequence, reverse	
primer sequence, PCR material and condition):	
☐ Familial Targeted Variant Analysis	Call to discuss
Gene name:	
Variant(s):	
Name of proband:	
Proband MRN:	
Relationship to proband:	
☐ Achondroplasia/Hypochondroplasia Variant Analysis	S0884
☐ Apert Variant Analysis	T0106
☐ Crouzon Syndrome with Acanthosis Nigricans Variant	T0441
Analysis	
☐ Factor V Leiden Variant Analysis	T0423
☐ KIF21A Select Exon Sequencing	T0868
☐ Melnick-Needles Syndrome Select Exon Analysis	T0635
☐ Mitochondrial 12S rRNA (MT-RNR1) Variants	S0920

Targeted Variant Analysis



Clinical Information

PATIENT NAM	E:	DOB:
REQUIRED: ICD-10 CODE(S):		
Provide Main Clinical Indication and Differential Di	agnosis/Diagnoses:	
COGNITIVE/DEVELOPMENTAL/BEHAVIORAL Global developmental delay Motor delay: Gross Fine	CARDIOVASCULAR ☐ Conotruncal anomaly ☐ Atrial ☐ Ventricular septal defect	SKELETAL/LIMB Limb shortening Upper Lower Right Left Limb anomaly
□ Speech delay □ Intellectual disability □ Learning disability □ Developmental regression □ Autism spectrum disorders □ Psychiatric symptoms	□ Cardiomyopathy: □ DCM □ HCM □ LVNC □ Coarctation of aorta □ Hypoplastic left heart □ Arrhythmia/conduction defect OTHER	☐ Thumb anomaly ☐ Post-☐ Polydactyly ☐ Pre-☐ Post-☐ Syn-☐ Ectro-☐ Arachno-dactyly ☐ Small ☐ Large ☐ Hands ☐ Feet ☐ Club foot ☐ Unilateral ☐ Bi-lateral ☐ Scoliosis ☐ Kyphosis ☐ Lordosis
OTHER GROWTH Stature: Short Tall Obesity Overgrowth Failure to thrive	GASTROINTESTINAL Tracheoesophageal fistula Gastroschisis Omphalocele Hirschsprung disease Chronic diarrhea	☐ Fracture(s) ☐ Wormian bones ☐ Vertebral anomaly ☐ Contractures OTHER
HEAD/BRAIN/FACE	☐ Constipation ☐ Recurrent vomiting ☐ Pyloric stenosis ☐ Gastroesophageal reflux	METABOLIC ☐ CPK abnormality ☐ Ketosis ☐ Amino ☐ Organic ☐ -acidemia ☐ -aciduria
☐ Micro- ☐ Macro-cephaly ☐ Abnormal head shape:	☐ Anal atresia ☐ Hepato- ☐ Spleno-megaly OTHER	SpecifyOTHER ENDOCRINE
□ Micro- □ Pro- □ Retro-gnathia □ Cleft: □ Lip □ Palate □ Abnormality of Mouth □ Abnormality of Nose	GENITOURINARY Kidneys Hydronephrosis Malformation	□ Diabetes: □ Type I □ Type II □ Hypo- □ Hyper-thyroidism □ Hypoparathyroidism □ Pheochromocytoma/paraganglioma
□ Abnormality of □ Eyes □ Vision □ Hypo- □ Hyper-telorism □ Abnormality of Eyebrows □ Synophrys □ Abnormality of Ears □ Hearing loss: □ Hearing loss: □ Sensorineural □ Conductive	 □ Nephrotic syndrome □ Tubulopathy □ Agenesis □ Bladder □ Ambiguous genitalia 	OTHER IMMUNOLOGIC Immunodeficiency OTHER
□ Abnormality of Teeth □ Abnormality of Neck □ Facial asymmetry □ Facial: □ Palsy □ Paralysis □ Weakness OTHER	☐ Hypospadias ☐ Cryptorchidism OTHER MUSCULAR/NEUROLOGICAL	HEMATOLOGIC ☐ Anemia ☐ Neutro- ☐ Pancyto- ☐ Thrombocyto-penia ☐ Increased bleeding ☐ Thrombosis
SKIN/HAIR Hyper- Hypo-pigmentation Café-au-lait spots	☐ Seizures Type ☐ Hypertonia ☐ Hypertonia ☐ Spasticity ☐ Movement disorder	☐ Transient abnormal myelopoiesis ☐ Juvenile myelomonocytic leukemia OTHER
□ Skin: □ Tumors □ Ichthyosis □ Abnormal Nails □ Alopecia □ Abnormal Hair: □ Quantity □ Texture	☐ Ataxia ☐ Chorea ☐ Dystonia ☐ Muscle weakness: ☐ Proximal ☐ Distal	Tumor type/Location Age of onset PREVIOUS TESTING/RESULT
□ Abnormal Connective Tissue □ OTHER □ PERINATAL HISTORY	☐ Neurodegeneration ☐ Stroke ☐ Cranial nerve ☐ Sleep disturbance	Chromosomes:
□ Prematurity weeks □ IUGR □ Oligo- □ Poly-hydramnios □ Cystic hygroma/increased NT	☐ Headache/migraine ☐ Neural tube defect ☐ Diaphragmatic hernia ☐ Umbilical hernia	Biopsy: Imaging: OTHER:
☐ H/o recurrent pregnancy losses FAMILY HISTORY (For complex family histories, attach add	OTHERditional pages):	
ETHNICITY:	CONSANGUINITY: □ NO □ YES. IF YES. SPE	CIFY RELATIONSHIP:



Informed Consent Signatures

PATIENT NAME:	D0B:
TEST(S) ORDERED:	

How To Use This Section

Providers and patients should review information about the test(s) being ordered. Information is available on our website: www.claritasgenomics.com. All patients/parents/guardians should sign the "Informed Consent" section below to indicate that consent has been given for this testing.

INFORMED CONSENT

By signing below, I, the patient/guardian, confirm the following:

- a) The risks, benefits, and limitations of the test have been described to me;
- b) I have had a chance to have my questions answered;
- c) I choose to have this test;
- d) No tests other than those authorized shall be performed on the sample.
- e) Any sample sent from a Provider from New York State will be destroyed at the end of the testing process or not more than 60 days after the sample was taken.

Patient signature, or guardian if patient is under 18

Date

When parental samples are sent for clinical genetic tests that are not "for the purpose of diagnosing or detecting an existing disease, illness, impairment, or disorder," [as per Massachusetts Ann. Laws ch. 111 section 70G (2000)] consent must be documented.

By signing below, the parent confirms the following:

- a) I understand the intent of testing a parent is to identify the presence or absence of genetic changes similar to that found in my child;
- b) I understand that the interpretation of my child's genetic testing result may change depending on whether or not the genetic change(s) is/are present in me. I understand that for this reason, Claritas Genomics will include my genetic test result in my child's report for the purpose of assisting with the interpretation of that test result;
- c) I have had a chance to have my questions answered;
- d) I choose to send my sample to Claritas Genomics where it may or may not be used depending on whether genetic changes were identified in my child;
- e) No tests other than those authorized shall be performed on my sample.
- f) I understand that if my sample is sent by a Provider from New York State, it will be destroyed at the end of the testing process or not more than 60 days after the sample was taken.

Parent signature	Print Name	Relationship to Patient (i.e., Mother or Father)	Date	
Parent signature	Print Name	Relationship to Patient (i.e., Mother or Father)	Date	



Billing Information

PATIENT NAME:			_ DOB:		
1. INSTITUTIONAL	BILLING				
Client Code	Enter the Client Code provided by Claritas Genor Registration Form, available at www.claritasgeno or toll-free 855-373-9003. Claritas will not begin	omics.com or by contacting Client Services	s: clientservices@claritasgenomics.com		
2. INSURANCE BIL					
Client Code	Enter the Client Code provided by Claritas Genomics' Client Service team. If you do not have a client code, complete the Client Code Registration Form, available at on our website or by contacting Client Services.				
Claritas Genomics will directly bill third party insurances. Required Information: • A legible photocopy, front and back, of the insurance card • A copy of the insurance authorization, if obtained • Completed Insurance Billing information requested below Claritas Genomics will perform an insurance benefits investigation and/or prior authorization, when requested. Please see the insurance billing section on our website for additional information and requirements. Claritas will not begin testing until all information is complete and obtained.					
PRIMARY INSURANCE		SECONDARY INSURANCE			
Policyholder's Name		Policyholder's Name			
Policyholder's Date of Birth	(MM/DD/YY) Relationship to Patient	Policyholder's Date of Birth (MM/DD/YY)	Relationship to Patient		
Insurance Carrier	Insurance Carrier Phone Number	Insurance Carrier	Insurance Carrier Phone Number		
Policy Number		Policy Number			
Group Number	Auth Number	Group Number	Auth Number		
Insurance Address	City/State/Zip	Insurance Address	City/State/Zip		
Policyholder's Signature	Date	Policyholder's Signature	Date		
Patient/Family Acknowledgment I (The Insured) acknowledge that the information provided by me is true to the best of my knowledge. For billing my insurance company: I hereby authorize my insurance benefits to be paid directly to Claritas Genomics and authorize them to release medical information concerning my testing to my insurer to achieve payment. If applicable, I authorize Claritas Genomics to be my Designated Representative for purposes of appealing any denial of benefits to achieve payment. I understand that I am financially responsible for any amounts not covered by my insurer for this test. Claritas Genomics will bill patients/families for non-covered services, co-payments, deductibles, co-insurance, or balances as required by their insurer unless the patient meets certain financial criteria as defined in the Claritas Genomics Financial Assistance Program. I also understand that I am legally responsible for sending Claritas Genomics any money received directly from my health insurance company for performance of this test.					
Insured's printed name	Signature		Date		
Patient's/guardian's phone number, to be used to communicate benefits information					
3. SELF-PAY Complete the Credit Card Payment Form, available on our website or by calling our Client Services team toll-free at 855-373-9003.					
4. FINANCIAL ASSISTANCE PROGRAM Check to indicate that patient or family is experiencing economic hardships Check to indicate Provider is giving free medical care Include a completed Claritas Patient Financial Assistance Application, which is available on our website or by contacting Client Services.					

